ELAB vs PATH · rev $1.7M vs P/E 19, rev $1.61B
Elevai Labs, Inc. Common Stock (ELAB) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Elevai Labs, Inc. Common Stock (ELAB) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ELAB revenue for 2023-12-31 was $1.7M. Net income was -$4.3M. Revenue was up 123.5% from 2022-12-31 to 2023-12-31. ELAB currently screens at market cap $6.5M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ELAB currently screens at market cap $6.5M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ELAB and PATH stock pages for the full models.
Not investment advice.